Renal Elimination
Renal Elimination - Related Videos
01:23
Drug Elimination: Non-Renal Routes
0 Views •
2023
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
01:22
Drug Elimination by Renal Route: Tubular Reabsorption
0 Views •
2023
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
01:17
Drug Elimination by Renal Route: Glomerular Filtration
0 Views •
2023
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production takes place. A nephron has two main components: a renal corpuscle and a renal tubule. Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent...
01:15
Drug Elimination by Renal Route: Tubular Secretion
0 Views •
2023
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
06:38
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
0 Views •
Cited by 14 •
2016
Early stage hemodynamic dysfunction is critical to the development of kidney disease. Yet, detection methodologies are limited. Recent advances in sonography provide a noninvasive, accurate option for early detection of kidney injury. This study outlines a step-by-step, sonographic methodology for detecting kidney dysfunction using a drug-induced nephrotoxicity rat model.
FAQs
The amount excreted in urine represents the net result of three kidney processes. Glomerular filtration moves some drug from blood into the forming urine, while active tubular secretion can add drug to that fluid. Tubular reabsorption moves some drug back from the tubule, reducing urinary loss. Their combined effects determine how much drug and metabolite leaves the body.
Chemical properties influence how much of a drug remains available for urinary excretion after filtration and secretion. They also affect the extent to which the substance is reabsorbed from the renal tubule. Consequently, two drugs exposed to the same kidney processes may produce different urinary amounts, which can alter overall clearance and treatment exposure.
When kidney function declines, removal of a renally eliminated drug or metabolite can decrease. Lower clearance may allow concentrations to remain elevated for longer, extending the drug’s half-life and increasing the possibility of accumulation during continued treatment. Pharmacology therefore connects renal function with safety decisions, particularly when exposure could become excessive or toxic.
Renal elimination contributes to a drug’s clearance, which describes how efficiently the body removes it from circulating exposure. A reduction in renal clearance can lengthen half-life because the drug takes more time to leave the body. Interpreting these measures together helps explain changing concentrations and supports evaluation of whether treatment exposure may become inadequate or excessive.
Dose selection can incorporate the patient’s renal function and the expected contribution of kidney removal. If elimination is reduced, clinicians may need to account for the potential increase in exposure, longer half-life, or accumulation during therapy. This pharmacological assessment helps balance effective treatment against safety concerns and provides a basis for medication monitoring.
Monitoring should consider whether kidney function is sufficient to maintain the expected removal of the drug and its metabolites. Changes that reduce elimination may be reflected by prolonged exposure or accumulation, while excessive removal could contribute to ineffective therapy. Linking renal function with treatment response and safety findings helps identify when pharmacological management may need reassessment.